For example, a phase 2 trial is underway, assessing nivolumab in combination with BMS-986253, an anti-IL-8 mAb, or cabiralizumab, an anti-CSF1R mAb, both of which target TAMs, either in terms of dampening their pro-tumor function or in reducing their numbers in the TME, respectively [88]. The gene discussed is CXCL8; the disease is neoplasm.